Check out this quest on Galxe: https://t.co/cD41w8BqKG via @Galxe

Verifying my Twitter account for my #GalxeID gid:enUVeug49ZcPY2zvSbv8CB @Galxe

April #RheumatologyAwarenessMonth Let’s start with MBBS grads — the first contact for many patients. Our study shows: ⚠️ Low confidence in rheumatology when compared to other specialities ⚠️Lack of awareness about common Msk illnesses https://t.co/ISk7VloAP2 #rheumtwitter

A 64 year old male diabetic , no retinopathy mild renal dysfunction with hypertension with minimal proteinuria, past h/o cva underwent renal biopsy - f/s/0 fabrys disease . How common is this presentation at this age ? How do we approach now ? @askrenal @drmjkulkarni

Recognize and Mitigate the Contrast Associated AKI @goKDIGO @NephJC infographic by @JasmineNephro

🔴ABG Analysis by @PTFlashcards

#ShortFactSaturday💡 BD vs SLE– Ulcers in both but different stories ! 🔹Behçet’s Disease→ Oral ulcers is a Symptom 🔹 SLE → Oral ulcers is a Sign #Rheumtwitter #medtwitter

🫘Approach to Resistant Hypertension https://t.co/l33Nnu9WN9

I made it to #ISNWCN 🇮🇳 #WCN25 🇮🇳 … well, kinda … #Nephpearls Thank you 🙏🏼 @deniise_am and @krithicism for the tag 👉🏼 https://t.co/GSQb4WovBu 👉🏼 https://t.co/JONWZ2NzHp

How are their MOA different ? 1. Rtx depends on Complement dependent cytotoxicity > ADCC ; Obinitizumab has more ADCC > CDC 2. Direct cell death by obinitizumab 3. Rituximab induced CDC, reduces CD20 expression on the B cells making them less accessible over time

Never Lose Hope! Lessons from CD20 depletion Ritux (LUNAR) : Failed Obinitizumab : NOBILITY (Phase II) and REGENCY (Phase III): Success The now available REGENCY speaks volumes on why science evolves. What fails today may succeed tomorrow! #LupusNephritis #Rheumtwitter (1/3)

Newer therapeutic strategies for treatment of LN #ISNWCN2025

Hi any protocol or guidelines regarding restarting heparin during hd in a patient with hemorrhagic CVA @pradeepshenoy @arvindcanchi @askrenal @drmjkulkarni

🤔 Do you routinely prescribe bicarbonate for your CKD patients? KDIGO 2024 updates have lowered the level of recommendation for bicarbonate therapy! 📉 🔹 New Threshold: Start supplementation at serum bicarb levels of 18, down from 22. Studies show that correction to normal

KDIGO 2024 Lupus Nephritis Guidelines - Visual Abstract https://t.co/5ZGvEp2wWy

Thanks to organizers for giving me an opportunity and for beautifully organizing the event @sreebhushan @drmanishasahay @SwarnalathaGud2 @myadla

Excellent scientific content , learnt new concepts , got an opportunity to share my thoughts on the topic assigned to me , a kind of social gathering nice to meet my teacher’s and colleagues overall a comprehensive package @ISNSCCON_2024

🩺 Dr. Pramod GR’s comprehensive overview of Hyperparathyroidism’s medical management at #ISNSCCON2024 was enlightening, offering effective strategies for clinicians. @ISNSCCON_2024 @ISNkidneycare #ISNSCCON2024

⭕ A quick recap on most commonly used phosphate binders 🌟Niacin and Tenapanor - new phosphate binders acting in the gut ▶️Role of Vitamin D analogs @ISNkidneycare @ISNSCCON_2024 #ISNSCCON2024

@PramodNephro A shoutout to the months of research you did before the talk ! This is just the first step , way more to go #isnsccon2024